|Title||Supplementation with Sea Vegetables and Exerts Metabolic Benefits in Diet-Induced Obesity in Mice.|
|Publication Type||Journal Article|
|Year of Publication||2020|
|Authors||Mendez RL, Miranda C, Armour CR, Sharpton TJ, Stevens JFrederik, Kwon JYeon|
|Journal||Curr Dev Nutr|
|Date Published||2020 May|
Background: Sea vegetables are rich sources of nutrients as well as bioactive components that are linked to metabolic health improvement. Algal polysaccharides improve satiety and modulate gut microbiota while proteins, peptides, and phenolic fractions exert anti-inflammatory, antioxidant, and antidiabetic effects.
Objective: We tested the hypothesis that dietary supplementation with either Pacific dulse (, red algae) or wakame (, brown algae) could remediate metabolic complications in high-fat diet-induced obesity.
Methods: Individually caged C57BL/6J mice ( = 8) were fed ad libitum with either a low-fat diet (LFD), 10% kcal fat; high-fat diet (HFD), 60% kcal fat; HFD + 5% (wt:wt) dulse (HFD + D); or HFD + 5% (wt:wt) wakame (HFD + W) for 8 weeks. Food intake and weight gain were monitored weekly. Glucose tolerance, hepatic lipids, fecal lipids, and plasma markers were evaluated, and the gut microbiome composition was assessed.
Results: Despite the tendency of higher food and caloric intake than the HFD ( = 0.04) group, the HFD + D group mice did not exhibit higher body weight, indicating lower food and caloric efficiency (< 0.001). Sea vegetable supplementation reduced plasma monocyte chemotactic protein (MCP-1) (< 0.001) and increased fecal lipid excretion (< 0.001). Gut microbiome analysis showed that the HFD + D group had higher alpha-diversity than the HFD or LFD group, whereas beta-diversity analyses indicated that sea vegetable-supplemented HFD-fed mice (HFD + D and HFD + W groups) developed microbiome compositions more similar to those of the LFD-fed mice than those of the HFD-fed mice.
Conclusion: Sea vegetable supplementation showed protective effects against obesity-associated metabolic complications in C57BL/6J male mice by increasing lipid excretion, reducing systemic inflammatory marker, and mitigating gut microbiome alteration. While the obese phenotype development was not prevented, metabolic issues related to lipid absorption, inflammation, and gut microbial balance were improved, showing therapeutic promise and warranting eventual mechanistic elucidations.
|PubMed Central ID||PMC7245532|